Does UnitedHealthcare Cover AndroGel?

UnitedHealthcare Formulary Placement for AndroGel

AndroGel sits on Tier 3 (preferred brand) of most UnitedHealthcare commercial formularies. Generic testosterone gel 1%, manufactured by Teva and Perrigo, occupies Tier 1 or Tier 2 on the same formularies, which explains why UHC steers prescriptions toward generics first. The FDA-approved prescribing information for AndroGel specifies its indication for replacement therapy in adult males with conditions associated with a deficiency or absence of endogenous testosterone [1].

Formulary tier placement directly affects out-of-pocket cost. Tier 1 generics on UHC plans typically carry copays of $10 to $25, while Tier 3 brands like AndroGel range from $50 to $100 per fill [2]. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by consistently low morning serum testosterone, without specifying a required formulation. This guideline flexibility is what allows insurers to mandate generic-first step therapy [3].

UHC updates its formulary quarterly. Patients and prescribers can verify current tier placement by searching "testosterone" on the UnitedHealthcare prescription drug list or calling the member services number on the back of the insurance card. Employer-sponsored plans may use custom formularies that differ from the standard national list, so confirming coverage for each specific plan is necessary before assuming Tier 3 access.

Prior Authorization Requirements

UnitedHealthcare requires prior authorization before covering AndroGel. The PA process is moderate in difficulty compared to specialty biologics but still demands clinical documentation. According to UHC's pharmacy management policies, prescribers must submit evidence of two separate morning serum total testosterone levels below 300 ng/dL, drawn between 8 AM and 10 AM [4]. The Endocrine Society guideline supports this threshold, recommending confirmatory testing on at least two occasions using a reliable assay [3].

Required documentation typically includes:

• Two fasting morning testosterone levels (total testosterone by LC-MS/MS preferred)
• Signs and symptoms of hypogonadism (fatigue, decreased libido, erectile dysfunction, loss of muscle mass)
• Exclusion of reversible causes such as opioid use, obesity-related suppression, or pituitary pathology
• LH and FSH levels to differentiate primary from secondary hypogonadism
• PSA and hematocrit baseline values

The American Urological Association's 2018 guideline on testosterone deficiency confirms that total testosterone below 300 ng/dL on two separate occasions establishes a biochemical diagnosis [5]. Meeting both biochemical and symptomatic criteria strengthens the PA submission.

PA decisions typically arrive within 72 hours for standard requests. Urgent requests tied to documented symptoms may receive 24-hour turnaround. If PA is denied, the explanation of benefits letter will specify the exact reason, which is critical for structuring an appeal.

Step Therapy: What UHC Requires First

Most UnitedHealthcare plans enforce step therapy before approving brand AndroGel. Step therapy, sometimes called "fail first," requires that a patient try and document inadequate response to a lower-cost alternative. For testosterone replacement, this usually means a 60- to 90-day trial of generic testosterone gel 1% or injectable testosterone cypionate [6].

Injectable testosterone cypionate costs approximately $30 to $75 per month without insurance, per GoodRx pricing data, making it the least expensive TRT option. The landmark Testosterone Trials (TTrials), a coordinated set of seven placebo-controlled studies involving 790 men aged 65 and older with testosterone below 275 ng/dL, used AndroGel 1% as the study drug and demonstrated improvements in sexual function, physical activity, and bone mineral density over 12 months [7].

To satisfy step therapy, the prescriber must document one of the following:

• Therapeutic failure on generic testosterone gel (persistent symptoms or testosterone levels remaining below target after 60+ days at adequate doses)
• Adverse reaction to the generic formulation (skin irritation, allergic contact dermatitis)
• Clinically significant reason the alternative is inappropriate (e.g., needle phobia preventing injectable use, documented skin reaction to generic gel excipients)

A 2016 meta-analysis in the Journal of Clinical Endocrinology & Metabolism examining 156 randomized controlled trials of testosterone therapy found that transdermal formulations produced more physiologic diurnal testosterone patterns compared to injections, which create supraphysiologic peaks and subtherapeutic troughs [8]. This pharmacokinetic argument can support a medical necessity letter if injectables are the step therapy requirement.

How to Appeal a UnitedHealthcare Denial of AndroGel

UHC provides a two-level internal appeal process followed by an external independent review organization (IRO) appeal. Each level has specific deadlines that patients must observe.

Level 1 Internal Appeal. Must be filed within 180 days of the denial. The prescriber should submit a letter of medical necessity citing specific clinical evidence. Reference the Endocrine Society guideline recommendation that testosterone formulation should be an individualized decision between clinician and patient [3]. Include documented step therapy failure, lab results, symptom logs, and any adverse reactions to alternatives.

Level 2 Internal Appeal. If Level 1 is upheld, a second appeal must be filed within 60 days. This review is conducted by a different medical director. New clinical evidence not included in Level 1 strengthens this submission. A 2020 study in JAMA Internal Medicine found that 40% to 60% of initial insurance denials for prescription medications are overturned on appeal [9], so persistence matters.

External IRO Review. After exhausting internal appeals, patients may request an independent external review. The IRO is a third-party organization with no financial ties to UHC. The Employee Benefits Security Administration (EBSA) oversees this process for employer-sponsored plans under ERISA, while state insurance departments handle individual and small-group market plans.

Key tips for a successful appeal:

• Quote specific guideline language, not vague clinical reasoning
• Include a timeline of failed alternatives with lab values before and after
• Have the prescribing physician, not office staff, sign the appeal letter
• Request a peer-to-peer review between the prescriber and UHC's reviewing physician

Cost Breakdown: AndroGel With and Without UHC Coverage

The manufacturer list price for AndroGel 1.62% is approximately $510 per month for a 30-day supply. This price has remained relatively stable since AbbVie's last pricing adjustment. Without any insurance, cash-pay options through discount programs run between $400 and $510 per month [10].

With UnitedHealthcare Tier 3 coverage after PA approval, patients typically pay $50 to $100 per fill depending on plan design. Plans with coinsurance rather than flat copays may charge 25% to 40% of the negotiated rate, which could mean $75 to $150 per month. A 2019 analysis published in Urology found that out-of-pocket costs for branded testosterone formulations were the leading cause of treatment discontinuation, with 34% of men citing cost as their primary reason for stopping TRT [11].

Generic testosterone gel 1% (the bioequivalent of the original AndroGel 1% formulation) costs $40 to $120 per month at cash price. With UHC Tier 1 or Tier 2 coverage, the copay drops to $10 to $35. The FDA's Orange Book lists approved generic testosterone gel products with therapeutic equivalence ratings of AB, confirming bioequivalence to the reference product [12].

For patients with commercial UHC insurance, the AbbVie AndroGel savings card may cover the difference between the patient's copay and a target price (often reducing out-of-pocket to $0 to $75). This card cannot be used with government insurance programs (Medicare, Medicaid, Tricare). Eligibility and terms change annually, so patients should verify directly with AbbVie's patient support program.

Clinical Criteria: Why Documentation Matters for Coverage

Insurance coverage for testosterone replacement is tightly linked to clinical appropriateness. The FDA's 2015 safety communication restricted testosterone product indications to men with hypogonadism caused by specific medical conditions (testicular disorders, pituitary disorders, genetic conditions) rather than age-related decline alone [13]. This distinction matters for PA approval.

UHC's clinical criteria align with this FDA guidance. Coverage is generally limited to:

• Primary hypogonadism: testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, or chemotherapy/radiation
• Secondary hypogonadism: pituitary-hypothalamic injury from tumors, trauma, radiation, or confirmed idiopathic hypogonadotropic hypogonadism

The T-Trials demonstrated that testosterone gel therapy improved sexual function scores by 0.58 points on the PDQ-Q4 scale (P<0.001) and increased 6-minute walking distance by 6.0 meters compared to placebo in older men with low testosterone [7]. These functional outcomes, while statistically significant, show modest absolute effect sizes, which is why insurers demand rigorous diagnostic criteria before covering treatment.

A 2017 systematic review published in Annals of Internal Medicine evaluated testosterone therapy across 27 trials (N=3,431) and concluded that testosterone consistently improved sexual function and modestly improved mood and depressive symptoms, while effects on vitality and physical function remained less certain [14]. Citing this calibrated evidence in a PA submission shows the reviewing pharmacist that the prescriber understands both the benefits and the limitations of therapy.

Baseline and monitoring labs that strengthen PA documentation include hematocrit (must be below 54%), PSA (rule out prostate cancer per the American Urological Association screening guideline), lipid panel, and hepatic function panel [15]. The Endocrine Society recommends checking hematocrit at 3 to 6 months and then annually, with dose reduction or phlebotomy if hematocrit exceeds 54% [3].

UnitedHealthcare Medicare Advantage and AndroGel

Medicare Advantage plans administered by UnitedHealthcare (AARP Medicare Complete, for example) follow Medicare Part D formulary rules, which differ from commercial plan coverage. AndroGel is typically covered under Part D but may sit on Tier 4 (non-preferred brand) or Tier 5 (specialty) depending on the specific plan.

The coverage gap ("donut hole") affects out-of-pocket costs. In 2026, once a patient reaches $5 to 030 in total drug costs, they enter the coverage gap where they pay 25% of the drug's cost until reaching catastrophic coverage at $8 to 000 in true out-of-pocket spending [16]. At AndroGel's list price, patients could reach the gap within a few months.

A 2021 cohort study in the Journal of the Endocrine Society analyzing Medicare claims data found that testosterone prescribing in men over 65 declined by 50% between 2013 and 2016 following FDA safety warnings, then partially rebounded after the TRAVERSE cardiovascular safety trial (N=5,246) demonstrated non-inferiority of transdermal testosterone versus placebo for major adverse cardiovascular events (MACE HR 0.96 to 95% CI 0.78 to 1.17) [17, 18]. TRAVERSE data may help support PA submissions for Medicare Advantage patients where cardiovascular risk had previously been cited as a denial reason.

The AbbVie savings card is not valid for Medicare beneficiaries. Medicare patients seeking cost relief should explore state pharmaceutical assistance programs, the Medicare Extra Help/Low-Income Subsidy program, or switching to generic testosterone gel or injectable testosterone cypionate.

Switching From AndroGel to a Covered Alternative

If PA for brand AndroGel is denied and appeals fail, several therapeutically equivalent alternatives remain covered by UHC.

Generic testosterone gel 1% (Tier 1 or 2) provides the same active ingredient. A 2014 pharmacokinetic study confirmed that FDA-approved generic testosterone gels achieve comparable steady-state testosterone levels to the branded product [19]. Application site and absorption characteristics are similar, though patients occasionally report differences in gel vehicle texture or drying time.

Testosterone cypionate injection (Tier 1) requires intramuscular or subcutaneous injection every 1 to 2 weeks. A 2022 study in the Journal of Urology found that subcutaneous testosterone cypionate injections produced equivalent testosterone levels to intramuscular injections with less injection-site pain (VAS score 1.2 vs. 3.4, P<0.01) [20].

Natesto (testosterone nasal gel) and Jatenzo (oral testosterone undecanoate) are newer formulations that may or may not appear on UHC formularies. Both carry higher costs and may require separate PA processes. The Jatenzo prescribing information notes its specific indication for primary and hypogonadotropic hypogonadism and includes a REMS requirement due to blood pressure effects [21].